title: Broadly neutralizing antibodies: An approach to control HIV-1 infection.
abstract: Although available antiretroviral therapy (ART) has changed human immunodeficiency virus (HIV)-1 infection to a non-fatal chronic disease, the economic burden of lifelong therapy, severe adverse ART effects, daily ART adherence, and emergence of ART-resistant HIV-1 mutants require prospecting for alternative therapeutic modalities. Indeed, a growing body of evidence suggests that broadly neutralizing anti-HIV-1 antibodies (BNAbs) may offer one such feasible alternative. To evaluate their therapeutic potential in established HIV-1 infection, we sought to address recent advances in pre-clinical and clinical investigations in this area of HIV-1 research. In addition, we addressed the obstacles that may impede the success of such immunotherapeutic approach, suggested strategic solutions, and briefly compared this approach with the currently used ART to open new insights for potential future passive immunotherapy for HIV-1 infection.
authors.affiliation: a Department of Medical Laboratory Sciences , College of Applied Medical Sciences, Jordan University of Science and Technology , Irbid , Jordan.
authors.forename: Mahmoud Mohammad
authors.initials: MM
authors.lastname: Yaseen
authors.affiliation: b Department of Public Health, College of Nursing , University of Benghazi , Benghazi , Libya.
authors.forename: Mohammad Mahmoud
authors.initials: MM
authors.lastname: Yaseen
authors.affiliation: c Department of Clinical Pharmacy , College of Pharmacy, Jordan University of Science and Technology , Irbid , Jordan.
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Alqudah
mesh_terms: D000818:Animals; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*
chemical_list: D044966:Anti-Retroviral Agents; D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing
keywords: Broadly neutralizing antibodies; HIV-1 controllers; HIV-1 disease progression; passive administration